Alkermes sues Teva, Apotex, MSN over LYBALVI patents; enters VIVITROL AG deal with Amneal

Alkermes plc.

Filed patent lawsuits against Teva (8/15), Apotex (8/27), MSN (9/5) over generic LYBALVI; 30-month FDA stays triggered.
LYBALVI patents expiring 2032-2041; lawsuit amended 8/20 to include additional patent.
Entered authorized generic supply agreement with Amneal for VIVITROL, effective upon third-party ANDA launch.
Amneal may distribute AG VIVITROL for one year, supply limited to ~15% of 2024 unit sales; profit sharing.

item 1.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.